

8 March 2023



The Nifty ended 0.24% up at 17754.40. It opened on a negative note and traded in green throughout the day towards ending with a bullish candle on daily. However, chart pattern suggesting, weakness likely to persist as long as it trades below 17800 levels. Hence, staying cautious on rise is advised. The Nifty immediate range likely to be 17550-17800 with a negative bias.

On the Nifty hourly chart, pullback against ongoing retracement may find sellers on rise around critical MA band placed around 17800 levels. Staying cautious on rise is advised.

Nifty patterns on multiple periods suggesting; weakness likely to sustain as long as it trades below 17800. Index majors may find sellers on rise. Immediate range likely to be 17550-17800.

### Nifty Crucial Supports & Resistances-

**Supports- 17600, 17550 Resistances- 17800, 17900**

### Open Positional Calls-

**T+15 SELL-**

| Fut Segment | HINDALCO @ 420-425, TGT- 385, Closing SL- above 445

**T+30 INST POSITIONAL SELL-**

| Fut Segment | CAN BANK @ 310-315, TGT- 275, Closing SL- above 335

### Key Contents

Domestic News

### Page No.

8

## Nifty Intraday Chart



## Market in Retrospect

India's benchmark stock indices ended higher on Wednesday after rebounding in late trade, led by gains in auto, energy, and bank stocks.

Nifty index ended 0.24% higher, ended at 17,754. The broader markets represented by the Nifty 500 Index ended 0.28% higher, ending at 14,922. Among the sectorial indices, Nifty PSE was the top gainer gaining by 0.94%, followed by Nifty Auto gaining by 0.85%. Nifty Realty was the top loser losing by 0.68%.

Indusind Bank was the top gainer, gaining by 4.79%, followed by Adani Ports & SE and Adani Enterprises which gaining by 3.08% & 2.86%. Bajaj Finance was the top loser, losing by 2.25%, followed by Hindalco Industries and Tech Mahindra losing by 1.63% & 1.08%.

## Market Turnover (In Crore) 08-03-2023

Name	Last	Previous
NSE Cash	51066.51	52251.21
NSE F&O	18655937.04	22386073.62
BSE Cash	3,264.47	3,283.80
BSE F&O	25.66	15.08

## FII Derivatives Flow (In Crore) 08-03-2023

Instrument	Purchase	Sale	Net
Index Future	5207.90	5784.48	576.58
Index Option	1332485.34	1327936.91	4548.43
Stock Future	8452.31	8334.20	118.11
Stock Option	9310.45	9220.28	90.17

## Institutional Flow (In Crore) 08-03-2023

Institution	Purchase	Sale	Net
FII	11451.0	7779.44	3671.56
DII	4625.58	5563.38	937.8

## NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Indusind Bank	4.79	8.96	7227479	3237263
Adani Ports & SE	3.08	20.19	20232587	29074060
Adani Enterprises	2.86	49.55	13568243	26220600
Bajaj Auto	2.37	4.10	478922	380181
M&M	1.53	1.60	2370800	2074719

## NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Infosys	0.98	0.35	4137080	6125222
Apollo Enterprise	1.02	0.58	246734	264819
Tech Mahindra	1.08	2.00	2230530	2456493
Hindalco Industries	1.63	2.14	7044653	7017704
Bajaj Finance	2.25	1.89	1342795	685094

## Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>  
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>



## Sensex Intraday Chart



## Market in Detailed (Updated after 4:00 PM)

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	60348.09	123.63	0.21	2.35	0.75	2.95	10.43
Nifty	17754.40	42.95	0.24	2.60	0.78	4.01	8.62
BSE M Cap	24925.18	151.63	0.61	3.18	1.17	4.51	12.74
BSE S Cap	28173.46	77.43	0.28	3.04	0.78	5.33	9.70
Nifty MC 100	31119.25	159.20	0.51	3.33	0.53	3.88	12.00
BSE Auto	29916.84	282.65	0.95	2.36	1.17	1.00	33.32
BSE Capgoods	34813.43	423.64	1.23	2.81	1.49	0.25	31.13
BSE FMCG	16520.89	84.56	0.51	2.22	0.26	0.65	33.21
BSE Metal	19559.76	84.49	0.43	3.02	4.00	4.91	8.10
BSE Oil&Gas	17772.01	138.55	0.79	5.07	0.73	12.64	0.23
BSE Healthcare	21695.88	82.68	0.38	0.44	2.32	7.88	4.35
BSE Power	3536.86	62.24	1.79	7.30	0.19	22.15	7.93
BSE Realty	3256.03	16.52	0.50	3.30	0.63	8.61	2.18
BSE ConsDur	37944.83	168.28	0.44	1.29	1.72	7.00	6.96
BSE Bank	47009.50	194.84	0.42	3.07	0.03	5.41	21.41
BSE IT	29781.77	123.79	0.41	1.28	1.11	1.58	11.56

### Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	3.97	0.00	0.05	0.67	9.86	13.89	114.87
UK	3.80	0.03	0.68	1.09	14.58	22.89	162.52
Brazil	6.63	0.05	0.76	0.88	7.37	15.96	29.51
Japan	0.51	0.00	0.20	0.20	1.00	98.04	215.63
Australia	3.74	0.06	1.60	1.14	3.57	11.20	67.77
India	7.44	0.03	0.41	0.53	1.25	2.03	7.85
Switzerland	1.47	0.08	5.24	3.04	4.34	38.96	513.39
Germany	2.67	0.02	0.78	1.48	13.03	46.76	2284.82

### Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	82.06	0.14	0.17	0.55	0.53	0.46	6.27
USD Index	105.67	0.05	0.05	1.13	2.18	0.85	6.67
YUAN	6.96	0.00	0.06	1.33	2.44	0.07	9.24
GBP	1.18	0.00	0.10	1.55	1.91	3.20	9.62
EUR	1.05	0.00	0.09	1.21	1.62	0.16	3.30
YEN	137.26	0.10	0.07	0.78	4.27	0.43	15.73

### Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1298.00	40.00	3.18	18.11	115.26	6.28	44.81
Baltic Dirty	1487.00	2.00	0.13	2.20	22.59	28.82	4.42
SG Dubai HY	25.48	2.40	10.40	18.81	23.37	24.22	638.25

### Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	32856.46	574.98	1.72	0.61	3.22	2.74	0.69
Nasdaq	11530.33	145.41	1.25	0.65	3.19	4.05	9.89
S&P 500	3986.37	62.05	1.53	0.41	3.19	0.58	4.42
FTSE100	7912.28	7.34	0.09	0.04	0.34	5.89	13.61
CAC40	7331.08	8.95	0.12	1.33	2.96	10.27	22.93
DAX	15594.35	34.02	0.22	1.89	1.18	9.32	21.53
Mexico IPC	53068.73	855.46	1.59	0.59	0.11	3.90	0.41
Brazil Bovespa	104227.9	472.39	0.45	0.67	5.21	2.82	6.27
Russian RTS	951.38	6.88	0.72	0.54	3.10	13.25	1.54
Japan Nikkei	28444.19	135.03	0.48	3.37	3.12	1.95	15.08
Hang Seng	20051.25	483.23	2.35	2.76	7.27	0.76	2.79
Taiwan Index	15818.20	39.69	0.25	1.41	1.41	7.57	7.04
Shanghai Comp	3283.25	1.85	0.06	0.88	0.39	2.38	0.82
KOSPI	2431.91	31.44	1.28	0.79	2.00	1.79	7.26
Malaysia KLCI	1454.66	4.01	0.27	0.31	0.68	1.53	6.89
Jakarta Comp	6776.37	9.61	0.14	1.00	1.75	0.91	1.28
Philippine SE	6711.49	6.37	0.10	1.58	1.92	2.00	3.98
Thai Exch	1612.60	5.91	0.37	0.60	3.39	0.65	1.89

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	77.26	0.28	0.36	0.50	1.49	8.17	37.51
BRENT Crude	83.10	0.15	0.18	1.39	1.84	7.97	14.36
Natural Gas	2.62	0.07	2.49	6.79	5.77	45.69	26.67

### LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1814.87	1.17	0.06	1.20	3.25	1.42	11.51
Silver(\$/Ounce)	20.13	0.04	0.20	4.18	9.87	12.79	23.82
Aluminium	2300.75	33.25	1.42	1.15	7.45	6.19	38.35
Copper	8737.50	155.75	1.75	2.39	1.75	3.65	14.80
Zinc	2980.75	73.25	2.40	1.64	5.96	7.05	27.88
Lead	2082.00	33.65	1.59	1.00	0.19	5.20	14.89

### Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	179.30	3.25	1.78	2.32	2.08	12.48	19.67
Cotton	83.07	0.30	0.36	3.02	3.41	3.00	12.88
Sugar	20.95	0.07	0.33	1.85	5.44	13.18	13.12
Wheat	691.50	6.50	0.93	2.61	10.77	8.56	23.95
Soybean	1512.00	3.50	0.23	1.19	0.12	1.09	9.03

### **Air India says 15 pc of its total 1,825 pilots are female pilots**

Air India on Wednesday said 15 per cent of its 1,825 pilots are women pilots, making it an airline with the largest number of female pilots. To mark International Women's Day, the Tata Group-owned Air India, along with Air India Express and AirAsia India, has scheduled more than 90 all-women crew flights, and the carriers have been operating these all-women crew flights on international and domestic routes since March 1. According to the carrier, women constitute over 40 per cent of Air India's workforce, with 275 of its 1,825 pilots being women, representing 15 per cent of the cockpit crew strength and making it an airline having one of the largest numbers of female pilots. Air India CEO and Managing Director Campbell Wilson said India has the largest number of commercial women pilots in the world.

### **Alembic Pharmaceuticals gets USFDA nod for hypertension drug**

Alembic Pharmaceuticals Limited announced that it has received final approval from the US health regulatory, USFDA, for its abbreviated new drug application of Prazosin Hydrochloride Capsules, which is used for treatment of hypertension. The approved ANDA (abbreviated new drug application) is therapeutically equivalent to the reference listed drug product (RLD), Minipress Capsules, 1 mg, 2 mg, and 5 mg, of Pfizer Inc. Prazosin Hydrochloride Capsule, it said, is indicated for the treatment of hypertension, to lower blood pressure. Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg have an estimated market size of USD 50 million for 12 months ended December 2022, according to IQVIA. Alembic has a cumulative total of 183 ANDA approvals (160 final approvals and 23 tentative approvals) from the US Food & Drug Administration (USFDA). Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. It is one of the leaders in branded generics in India.

### **Ashok Leyland rolls out Embrace Equity programme**

Hinduja Group flagship company Ashok Leyland has launched a new campaign 'Embrace Equity' commemorating International Women's Day being celebrated on Wednesday, the company said. The initiative is an attempt to provide women with equal opportunities and the city-based firm has invited 100 women to New Delhi to be trained on driving commercial vehicles at its training institute. Ashok Leyland said recently it partnered with Delhi government's initiative - Mission Parivartan -- to train 180 women and many of them have now been employed as bus drivers with the Delhi Transportation Corporation. Traditionally, heavy commercial vehicle driving has been a man's forte, with this campaign, Ashok Leyland intends to break the barrier and inspire more women to get behind the wheels.

### **Future Enterprises admitted for insolvency**

After Future Retail, another Kishore Biyani company Future Enterprise has been admitted to insolvency resolution, requiring the firm to be auctioned to recover unpaid dues. In a regulatory filing, Future Retail said the Mumbai bench of the National Company Law Tribunal on March 7 "ordered the commencement of corporate insolvency resolution process (CIRP)". The NCLT appointed a resolution professional to manage the affairs of the company till it is sold to a successful bidder. With the commencement of CIRP, the management of the company now vest with the resolution professional and the powers of the board of directors stand suspended.

### CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
No events	

### Domestic Events

- No events

### Global Events

- The U.S. Initial Jobless Claims for March 04, 2023.
- Japan GDP for Q4 2022.



### **Analyst Certification:**

We /I, Jaydeb Dey Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.



### Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

---

### Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

---

### Contact us:

**SMIFS Limited.** (<https://www.smifs.com/>)

### Compliance Officer:

**Sudipto Datta,**

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)

---